Heptares Therapeutics Ltd. (Heptares), a wholly-owned subsidiary of Sosei Group Corporation (Tokyo Stock Exchange: TYO) based in Hertfordshire, UK, announced that it signed an agreement to acquire 100% in G7 Therapeutics AG, Switzerland (G7). G7 is a privately held biopharmaceutical company based in Schlieren, Switzerland. G7 has developed proprietary approaches for stabilizing G protein-coupled receptors (GPCR) called SaBRE and CHESS, which are different and highly complementary to the StaR® platform developed by Heptares. SaBRE and CHESS are of particular use where the target GPCR is present in very low numbers on cells and the methods are particularly powerful in the numbers of stabilizing mutations that can be identified in a short time for rapidly generating high quality GPCRs.

Heptares and the shareholders of G7 have agreed to a cash payment of CHF 12 m.

Homburger acts as lead counsel and advises Heptares with respect to Swiss law. The Homburger team is led by partner Ueli Huber (Corporate | M&A) and included partner Gregor Bühler (IP | IT), associates Marc Hanslin (Corporate | M&A), Roman Perrig (IP | IT), Karin Mattle (Corporate | M&A) and junior associate Nicolas Curchod (Corporate | M&A).